Due diligence of first-in-class monoclonal antibody candidate drug

Challenge: A biopharma company required expert due diligence for a potential transaction with a clinical stage biotech focusing in inflammation and fibrosis. Alacrita was commissioned to provide an...
Learn More

Technical & commercial due diligence of two pipeline cell therapy products

Challenge: Alacrita was engaged due diligence and valuation support by a listed clinical stage biotechnology company. The biotech needed to benchmark the technical strengths and weaknesses of two...
Learn More

Due diligence on reinvestment in VC-backed biotech

Challenge: A family office invested in a European, VC-backed company sought Alacrita's expert view of re-investing in the company, following a Phase III trial failure in the immunology space. The...
Learn More

Deal analysis for an anti-anaemia product

Challenge: A Middle East investor group was facing its first potential deal in the pharmaceuticals sector. It had pre-negotiated a deal with a group that had invented an approach to treating...
Learn More

Valuation of EPP drug to support in-licensing negotiation

Challenge: A privately capitalized biotech company in US, which was developing a pipeline of novel drugs to impact iron metabolism, wanted help with the valuation of in licensing opportunity for a...
Learn More

Due diligence on a AI-driven drug discovery platform

Challenge: A biotech company had developed an AI-driven drug discovery platform to discover phytocompounds and bioactives with the potential to impact human health. Alacrita was retained to conduct a...
Learn More

Ongoing DD support for research incubator and seed funder

Challenge: Our client, a research incubator, accelerator and seed funder within the biotechnology and life science arena, runs two programs in which companies/projects are selected through open...
Learn More

Valuation of Phase 3 Ready Alzheimer's Drug

Challenge: A clinical stage company developed two series of small molecules to treat Alzheimer Disease (AD) and other central nervous system (CNS) indications. Their lead asset aims for symptomatic...
Learn More

DD of a clinical stage therapeutic for rare neurodegenerative disorders

Challenge: A pharma company developing a first-in-class therapeutic to treat rare paediatric neurodegenerative disorders was nearing NDA approval in multiple indications and was ready to initiate...
Learn More

Ongoing Due Diligence Support

Challenge: A midsize speciality pharmaceuticals company has retained Alacrita to conduct a series of due diligence assessments to support its business development function. The client focuses on a...
Learn More

Assessing the BD landscape for in-licensing & acquisition deals

Challenge: A private equity client assessing a major investment asked Alacrita to research and assess the business development landscape for potential in-licensing or acquisition deals that could be...
Learn More

Due diligence of a biotech with a novel single chain antibody platform

Challenge: A European investor asked Alacrita to conduct a due diligence exercise on a company that had developed a novel single chain antibody platform with its lead product in ADC format ahead of a...
Learn More
1 2 3 4 5 ... 10
Next
Content not found

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2022 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Life Science Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.